Your browser doesn't support javascript.
loading
mRNA Display Identifies Potent, Paralog-Selective Peptidic Ligands for ARID1B.
Cremosnik, Gregor S; Mesrouze, Yannick; Zueger, Patrik; Furkert, David; Grandjean, Frédéric; Argoti, Dayana; Mermet-Meillon, Fanny; Bauer, Matthias R; Brittain, Scott; Rogemoser, Phuong; Yang, Winnie; Giovannoni, Jerome; McGregor, Lynn; Tang, Jenny; Knapp, Mark; Holzinger, Sandra; Buhr, Sylvia; Muller, Lionel; Leder, Lukas; Xie, Lili; Fernandez, Cesar; Nieto-Oberhuber, Cristina; Chène, Patrick; Galli, Giorgio G; Sesterhenn, Fabian.
Afiliação
  • Cremosnik GS; Global Discovery Chemistry, Novartis Biomedical Research, CH-4056 Basel, Switzerland.
  • Mesrouze Y; Disease area Oncology, Novartis Biomedical Research, CH-4056 Basel, Switzerland.
  • Zueger P; Global Discovery Chemistry, Novartis Biomedical Research, CH-4056 Basel, Switzerland.
  • Furkert D; Discovery Sciences, Novartis Biomedical Research, CH-4056 Basel, Switzerland.
  • Grandjean F; Discovery Sciences, Novartis Biomedical Research, CH-4056 Basel, Switzerland.
  • Argoti D; Global Discovery Chemistry, Novartis Biomedical Research, Emeryville, California 94608, United States.
  • Mermet-Meillon F; Disease area Oncology, Novartis Biomedical Research, CH-4056 Basel, Switzerland.
  • Bauer MR; Global Discovery Chemistry, Novartis Biomedical Research, CH-4056 Basel, Switzerland.
  • Brittain S; Discovery Sciences, Novartis Biomedical Research, Cambridge, Massachusetts 02139, United States.
  • Rogemoser P; Discovery Sciences, Novartis Biomedical Research, Cambridge, Massachusetts 02139, United States.
  • Yang W; Discovery Sciences, Novartis Biomedical Research, Cambridge, Massachusetts 02139, United States.
  • Giovannoni J; Discovery Sciences, Novartis Biomedical Research, CH-4056 Basel, Switzerland.
  • McGregor L; Discovery Sciences, Novartis Biomedical Research, Cambridge, Massachusetts 02139, United States.
  • Tang J; Global Discovery Chemistry, Novartis Biomedical Research, Emeryville, California 94608, United States.
  • Knapp M; Global Discovery Chemistry, Novartis Biomedical Research, Emeryville, California 94608, United States.
  • Holzinger S; Discovery Sciences, Novartis Biomedical Research, CH-4056 Basel, Switzerland.
  • Buhr S; Discovery Sciences, Novartis Biomedical Research, CH-4056 Basel, Switzerland.
  • Muller L; Discovery Sciences, Novartis Biomedical Research, CH-4056 Basel, Switzerland.
  • Leder L; Discovery Sciences, Novartis Biomedical Research, CH-4056 Basel, Switzerland.
  • Xie L; Discovery Sciences, Novartis Biomedical Research, Emeryville, California 94608, United States.
  • Fernandez C; Discovery Sciences, Novartis Biomedical Research, CH-4056 Basel, Switzerland.
  • Nieto-Oberhuber C; Global Discovery Chemistry, Novartis Biomedical Research, CH-4056 Basel, Switzerland.
  • Chène P; Disease area Oncology, Novartis Biomedical Research, CH-4056 Basel, Switzerland.
  • Galli GG; Disease area Oncology, Novartis Biomedical Research, CH-4056 Basel, Switzerland.
  • Sesterhenn F; Discovery Sciences, Novartis Biomedical Research, CH-4056 Basel, Switzerland.
ACS Chem Biol ; 19(5): 1142-1150, 2024 05 17.
Article em En | MEDLINE | ID: mdl-38655884
ABSTRACT
The ARID1A and ARID1B subunits are mutually exclusive components of the BAF variant of SWI/SNF chromatin remodeling complexes. Loss of function mutations in ARID1A are frequently observed in various cancers, resulting in a dependency on the paralog ARID1B for cancer cell proliferation. However, ARID1B has never been targeted directly, and the high degree of sequence similarity to ARID1A poses a challenge for the development of selective binders. In this study, we used mRNA display to identify peptidic ligands that bind with nanomolar affinities to ARID1B and showed high selectivity over ARID1A. Using orthogonal biochemical, biophysical, and chemical biology tools, we demonstrate that the peptides engage two different binding pockets, one of which directly involves an ARID1B-exclusive cysteine that could allow covalent targeting by small molecules. Our findings impart the first evidence of the ligandability of ARID1B, provide valuable tools for drug discovery, and suggest opportunities for the development of selective molecules to exploit the synthetic lethal relationship between ARID1A and ARID1B in cancer.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Peptídeos / Fatores de Transcrição / RNA Mensageiro / Proteínas de Ligação a DNA Limite: Humans Idioma: En Revista: ACS Chem Biol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Peptídeos / Fatores de Transcrição / RNA Mensageiro / Proteínas de Ligação a DNA Limite: Humans Idioma: En Revista: ACS Chem Biol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Suíça
...